NEW YORK (TheStreet) -- Celgene (CELG) - Get Report stock is falling by 1.04% to $101.25 in early-morning trading on Thursday, following the release of the company's 2015 fourth quarter financial results.

Before the market open, the biopharmaceutical company posted adjusted earnings of $1.18 per share, up from $1.01 per share for the year-ago quarter.

Revenue increased year-over-year, to $2.56 billion from $2.09 billion for the 2014 fourth quarter.

Analysts expected adjusted earnings of $1.22 per share on revenue of $2.54 billion, according to Thomson Reuters.

For the fiscal 2016 first quarter, Celgene has forecast for adjusted earnings between $1.27 and $1.30 per share. Analysts have projected earnings of $1.30 per share. 

"In 2016, we will continue to leverage our global operations and advance our deep and diverse pipeline to accelerate the next generation of transformational medicines," CEO Bob Hugin said in a statement.

Separately, TheStreet Ratings team rates the stock as a "buy" with a ratings score of B.

TheStreet Recommends

Celgene's strengths such as its robust revenue growth, notable return on equity and expanding profit margins outweigh the fact that the company has had lackluster performance in the stock itself.

You can view the full analysis from the report here: CELG

TheStreet Ratings objectively rated this stock according to its "risk-adjusted" total return prospect over a 12-month investment horizon. Not based on the news in any given day, the rating may differ from Jim Cramer's view or that of this article's author.

Image placeholder title

CELG

data by

YCharts